BiotechTube

KPI-121 0.25% Ophthalmic Suspension + Vehicle of KPI-121 0.25% Ophthalmic Suspension

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye Syndromes

Conditions

Dry Eye Syndromes, Keratoconjunctivitis Sicca

Trial Timeline

Jun 1, 2016 → Oct 1, 2017

NCT ID
NCT02813265

About KPI-121 0.25% Ophthalmic Suspension + Vehicle of KPI-121 0.25% Ophthalmic Suspension

KPI-121 0.25% Ophthalmic Suspension + Vehicle of KPI-121 0.25% Ophthalmic Suspension is a phase 3 stage product being developed by Kala Pharmaceuticals for Dry Eye Syndromes. The current trial status is completed. This product is registered under clinical trial identifier NCT02813265. Target conditions include Dry Eye Syndromes, Keratoconjunctivitis Sicca.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT02813265Phase 3Completed
NCT02819284Phase 3Completed

Competing Products

20 competing products in Dry Eye Syndromes

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
28
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
33
clopidogrel + prasugrelDaiichi SankyoPhase 1
33
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
77
Placebo + PrasugrelDaiichi SankyoPhase 3
77
decitabine + azacitidineEisaiApproved
85
Galunisertib + PlaceboEli LillyPhase 2/3
65
TP-0184Sumitomo PharmaPhase 1/2
41
Epoetin alfaJohnson & JohnsonPhase 2
52
Placebo + Epoetin alfa + Placebo + Epoetin alfaJohnson & JohnsonPhase 3
77
BortezomibJohnson & JohnsonPhase 1/2
41
Azacitidine + VenetoclaxAbbViePhase 1
33
Venetoclax + Azacitidine + Cytarabine + Methotrexate + Hydrocortisone + Leucovorin + Dexamethasone + Vincristine + Doxorubicin + Dexrazoxane + Calaspargase Pegol + Erwinia asparaginaseAbbViePhase 1
33
venetoclax + azacitidineAbbViePhase 1
33
rosuvastatin calcium + atorvastatinAstraZenecaPhase 3
77
Ticagrelor + ClopidogrelAstraZenecaApproved
85
Ferric Carboxymaltose Injection [Ferinject]AstraZenecaApproved
85
Metoprolol + metoprolol plus morphineAstraZenecaApproved
85
Hydroxypropylmethylcellulose + CarboxymethylcelluloseMerckApproved
85
PembrolizumabMerckPhase 1
33

Other Products from Kala Pharmaceuticals

loteprednol etabonate 0.25% ophthalmic suspensionApproved
77
KPI-121 1% Ophthalmic Suspension dosed BID + Vehicle of KPI-121 Ophthalmic Suspension dosed BIDPhase 3
69
KPI-121 1% + Prednisolone acetatePhase 3
69
KPI-121 Ophthalmic Suspension + VehiclePhase 3
69
KPI-121 0.25% + KPI-121 1.0% + Vehicle of KPI-121 0.25% + Vehicle of KPI-121 1.0%Phase 3
69